IL186120A - Method for determining whether a test compound is an inhibitor of neurotrypsin - Google Patents

Method for determining whether a test compound is an inhibitor of neurotrypsin

Info

Publication number
IL186120A
IL186120A IL186120A IL18612007A IL186120A IL 186120 A IL186120 A IL 186120A IL 186120 A IL186120 A IL 186120A IL 18612007 A IL18612007 A IL 18612007A IL 186120 A IL186120 A IL 186120A
Authority
IL
Israel
Prior art keywords
neurotrypsin
agrin
gly
leu
pro
Prior art date
Application number
IL186120A
Other languages
English (en)
Other versions
IL186120A0 (en
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of IL186120A0 publication Critical patent/IL186120A0/en
Publication of IL186120A publication Critical patent/IL186120A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/64—X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/976—Trypsin; Chymotrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL186120A 2005-03-30 2007-09-20 Method for determining whether a test compound is an inhibitor of neurotrypsin IL186120A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102481 2005-03-30
PCT/EP2006/061152 WO2006103261A2 (en) 2005-03-30 2006-03-29 Inhibitors of neurotrypsin and determination thereof

Publications (2)

Publication Number Publication Date
IL186120A0 IL186120A0 (en) 2008-01-20
IL186120A true IL186120A (en) 2012-08-30

Family

ID=34939082

Family Applications (1)

Application Number Title Priority Date Filing Date
IL186120A IL186120A (en) 2005-03-30 2007-09-20 Method for determining whether a test compound is an inhibitor of neurotrypsin

Country Status (15)

Country Link
US (1) US7897364B2 (https=)
EP (1) EP1868989A2 (https=)
JP (1) JP4920675B2 (https=)
KR (1) KR20070116932A (https=)
CN (1) CN101193858B (https=)
AU (1) AU2006228150B2 (https=)
BR (1) BRPI0609654A2 (https=)
CA (1) CA2600791A1 (https=)
IL (1) IL186120A (https=)
MX (1) MX2007011961A (https=)
NO (1) NO20075461L (https=)
NZ (1) NZ562796A (https=)
RU (1) RU2424228C2 (https=)
WO (1) WO2006103261A2 (https=)
ZA (1) ZA200707359B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074813A2 (en) * 2006-12-21 2008-06-26 Neurotune Ag Optiogenin for the treatment of neural diseases
PL1990420T3 (pl) * 2007-05-10 2011-01-31 Neurotune Ag Sposób wykrywania aktywności neurotrypsyny in vivo, zastosowanie tego sposobu i zastosowanie C-końcowego fragmentu agryny 22 kDa jako biomarkera w diagnozowaniu i monitorowaniu zaburzeń związanych z neurotrypsyną
EP2295068A1 (en) * 2009-09-04 2011-03-16 Neurotune AG Modified agrin-fragment capable of restoring muscle strength for use as a medicament
EP2635559A2 (en) 2010-11-01 2013-09-11 Neurotune AG Neurotrypsin inhibitors
WO2012059443A2 (en) 2010-11-01 2012-05-10 Neurotune Ag Novel neurotrypsin inhibitors
EP2631657A1 (en) * 2012-02-25 2013-08-28 Neurotune AG Immunoassay for the detection of the 22kDa C-terminal fragment (CAF) of agrin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH692507A5 (de) * 1997-04-26 2002-07-15 Peter Prof Dr Sonderegger Neurotrypsin als aktive Verbindung in einem Medikament.
DE19919634C2 (de) * 1999-04-30 2001-06-07 Aventis Pharma Gmbh Test zur Bestimmung der Integrität komplexer Phospholipid/Lipid-Strukturen mit Hilfe synthetischer fluoreszenz-markierter Acylglyceride und dessen Anwendung zur Bestimmung der Aktivität von Lipasen
DE10247478A1 (de) * 2002-10-11 2004-06-24 Bioagency Ag Verfahren zur Bestimmung der enzymatischen Aktivität von Proteinen

Also Published As

Publication number Publication date
JP4920675B2 (ja) 2012-04-18
EP1868989A2 (en) 2007-12-26
KR20070116932A (ko) 2007-12-11
WO2006103261A9 (en) 2010-05-27
CN101193858A (zh) 2008-06-04
CA2600791A1 (en) 2006-10-05
JP2008538178A (ja) 2008-10-16
RU2424228C2 (ru) 2011-07-20
WO2006103261A3 (en) 2007-02-22
AU2006228150A1 (en) 2006-10-05
RU2007139754A (ru) 2009-05-10
WO2006103261A2 (en) 2006-10-05
AU2006228150B2 (en) 2011-09-29
US7897364B2 (en) 2011-03-01
US20090170950A1 (en) 2009-07-02
ZA200707359B (en) 2009-08-26
IL186120A0 (en) 2008-01-20
NO20075461L (no) 2007-11-20
BRPI0609654A2 (pt) 2010-04-20
MX2007011961A (es) 2008-03-14
CN101193858B (zh) 2012-01-04
NZ562796A (en) 2010-02-26

Similar Documents

Publication Publication Date Title
US6844180B2 (en) Serine protease genes related to DPPIV
Shi et al. The pro domain of β-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain
US5501969A (en) Human osteoclast-derived cathepsin
AU2002213138A1 (en) Novel serine protease genes related to DPPIV
Brakch et al. Role of prohormone convertases in pro-neuropeptide Y processing: coexpression and in vitro kinetic investigations
IL186120A (en) Method for determining whether a test compound is an inhibitor of neurotrypsin
US20020090373A1 (en) ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
US8034783B2 (en) Prodomain modulators of ADAM 10
CA2313828A1 (en) Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
WO2000008134A2 (en) HUMAN HtrA SERINE PROTEASE
KR100856360B1 (ko) 절단형 ｄａｎｃｅ, ｄａｎｃｅ 복합체, 및 이들을사용하는 방법
KR20060136471A (ko) 절단형 ｄａｎｃｅ, ｄａｎｃｅ 복합체, 및 이들을사용하는 방법
US7208311B2 (en) Catalytic domain of ADAM33 and methods of use thereof
JP6446700B2 (ja) ニューレグリン−１（Ｎｅｕｒｅｇｕｌｉｎ−１）部分ペプチド
HK1119156A (en) Inhibitors of neurotrypsin and determination thereof
Wu et al. Purification and characterization of recombinant human renin for X-ray crystallization studies
AU2006228068B2 (en) Novel serine protease genes related to DPPIV
WO2004020587A2 (en) Carboxypeptidase b related polypeptides and methods of use
NZ542643A (en) Serine protease genes related to Dipeptidyl peptidase IV

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees